Comparison of Whole Body DWI to FDG PET

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT06630845
Status
Recruiting

Conditions

  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fluorodeoxyglucose F18 — DRUG
    Given IV as part of routine imaging
  • Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI) — PROCEDURE
    Imaging procedure
  • Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI) — PROCEDURE
    Imaging procedure done concurrently with PET/MRI
  • General Electric (GE) SIGNA PET/MR — DEVICE
    Imaging device

Study Details

This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

Key Dates

Start date
Feb 6, 2025
Status verified
Mar 2026
Primary completion
Oct 31, 2027
Completion
Oct 31, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Whole Body DWI plus FDG PET/MRI
    Participants will receive 5 to 10 Megabecquerel (MBq) +/- 10% of 18F-fluorodeoxyglucose as an intravenous injection and undergo a FDG PET/MRI scan that will extend from the vertex to the mid-thighs. Imaging will be performed from vertex to mid-thighs using standard protocol. Participants may also obtain an optional second FDG PET/MRI with DWI within 6 months.

Primary Outcome Measure

Proportion of lesions characterized as positive [ Time Frame: Up to 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
877-827-3222
Thomas Hope, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

Related Studies